Elevance Health Inc.
NYSE:ELVMedical - Healthcare Plans
-$3.45 today
- Market cap
- $86.60B
- Beta
- 0.68
- P/E (TTM)
- 16.3
- EPS (TTM)
- $23.78
- Dividend yield
- 1.77%
Volume 1.91M
Average 1.68M
ELV Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Elevance Health Inc.NYSE: ELV
Operating Income · Q3 FY2026 · quarter ended Sep 2026
Operating income growth accelerates
Q3 FY2026 operating income of $2.15B rose 22.5% year over year, ahead of the -12.0% change in trailing-twelve-month operating income. Sequentially, it rose 4.3% from the prior quarter. Over 3 fiscal years it compounded at -1.4% a year.
Context
- Operating income amounted to 4.1% of revenue in FY2025, down 1.0 pp from a year earlier.
- Operating income increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 12 analysts of $9.32B (+14.9%) for the fiscal year ending Dec 2026, a step up from the -8.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $2.15B+4.3% QoQ
- Last fiscal yearDec 2025
- $8.11B-8.7% YoY
- LTMSep 2026
- $7.46B-12.0% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- 8.11B USD
- Year-over-year change
- -8.7%
- 4-year CAGR
- -2.4%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.11B | -8.7% |
| FY2024 | 2024-12-31 | 8.89B | +1.6% |
| FY2023 | 2023-12-31 | 8.75B | +3.5% |
| FY2022 | 2022-12-31 | 8.45B | -5.5% |
| FY2021 | 2021-12-31 | 8.95B | — |
Operating Income vs competitors
How ELV compares with its peers on the latest reported figures
- ELV's LTM Sep 2026 operating income of $7.46B is the 4th highest of the 9 companies compared; the peer median is $1.31B.
- Its year-over-year change of -12.0% is the 7th highest of 9, against a peer median of -1.4%.
- Operating income amounts to 3.7% of revenue for ELV, versus a peer median of 2.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $23.92B | -9.2% | -12.6% | 5.3% | |
| LTM Sep 2026 | $9.58B | +4.6% | +2.6% | 3.3% | |
| LTM Jun 2026 | $8.29B | -7.4% | +9.3% | 2.0% | |
| LTM Sep 2026 | $7.46B | -12.0% | -1.4% | 3.7% | |
| LTM Sep 2026 | $1.99B | +26.0% | -25.9% | 1.3% | |
| LTM Jun 2026 | $624.1M | +567.8% | — | 4.1% | |
| LTM Sep 2026 | $172M | -87.0% | -17.3% | 0.4% | |
| LTM Mar 2026 | $35.65M | +154.1% | — | 0.8% | |
| LTM Jun 2026 | -$5.46B | -384.9% | — | 2.8% | |
| Peer median (excluding ELV) | $1.31B | -1.4% | -12.6% | 2.4% | |
Competitors are the stored peer set for ELV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 138.64B | 156.6B | 171.34B | 176.81B | 199.13B |
| Cost of Revenue | 102.65B | 116.64B | 124.33B | 127.57B | 148.22B |
| Gross Profit | 35.99B | 39.95B | 47.01B | 49.24B | 50.9B |
| Gross Margin | 26.0% | 25.5% | 27.4% | 27.9% | 25.6% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses | 27.05B | 31.5B | 38.27B | 40.36B | 42.79B |
| Depreciation & Amortization | 1.3B | 1.68B | 1.75B | 1.39B | 1.55B |
| EBITDA | 10.03B | 10.13B | 10.49B | 10.48B | 9.66B |
| EBITDA Margin | 7.2% | 6.5% | 6.1% | 5.9% | 4.9% |
| Operating Income | 8.95B | 8.45B | 8.75B | 8.89B | 8.11B |
| Operating Margin | 6.5% | 5.4% | 5.1% | 5.0% | 4.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 798M | 851M | 1.03B | 1.19B | 1.4B |
| Other Income / Expenses | (1.02B) | (851M) | (1.03B) | (984M) | (1.4B) |
| Income Before Tax | 7.93B | 7.6B | 7.72B | 7.9B | 6.71B |
| Pre-Tax Margin | 5.7% | 4.9% | 4.5% | 4.5% | 3.4% |
| Income Tax Expense | 1.83B | 1.71B | 1.72B | 1.93B | 1.05B |
| Net Income | 6.1B | 5.89B | 5.99B | 5.98B | 5.66B |
| Net Margin | 4.4% | 3.8% | 3.5% | 3.4% | 2.8% |
| EPS (Basic) | 25.25 | 24.56 | 25.38 | 25.81 | 25.18 |
| EPS (Diluted) | 24.73 | 24.28 | 25.22 | 25.68 | 25.12 |
| Weighted Avg Shares | 243.8M | 240M | 233.07M | 232.87M | 221.8M |
| Weighted Avg Shares (Diluted) | 246.8M | 242.8M | 237.4M | 232.9M | 221.8M |
Elevance Health Inc.
NYSE:ELV
Intrinsic Alpha fair value
Locked
Current Price
$400.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.